Daily Journal Staff Writer
San Diego-based breast cancer drug developer Seragon Pharmaceuticals Inc. relied on Wilson Sonsini Goodrich & Rosati PC to handle its sale to Roche Holding AG, one of the world's largest purveyors of cancer treatment drugs, in a deal announced Wednesday.
Roche is paying $725 million in cash upfront, but Seragon could net up to an additional $1 billion if it meets certain development miles...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In